Tiotropium as add-on to inhaled corticosteroids significantly improves asthma control as reflected by the ACQ responder rate
O Schmidt, HAM Kerstjens, E Bleecker, E Meltzer, T Casale, E Pizzichini, M Engel, LJ Bour, CB Verkleij, PM Moroni-Zentgraf, ED Bateman · Pneumologie · 2014 · Heft 02
Bibliografische Angaben
Zusammenfassung
Background: Despite current medications, there remains an unmet need for asthma control in patients with moderate asthma receiving at least ICS. We analysed ACQ (asthma control questionnaire) data in patients treated with once-daily long-acting anticholinergic bronchodilator tiotropium who had symptomatic asthma despite treatment with medium-dose ICS (400 – 800 µg budesonide equivalent). Methods: 2103 patients were randomised in 2 identical Phase III, double-blind, double-dummy, parallel-group studies (NCT01172808 and NCT01172821). Patients received tiotropium 2.5 µg or 5 µg or placebo (all doses via Respimat® S…
